BioWorld6h
Corcept looks to NDA following strong phase III ovarian cancer data
Relacorilant, a cortisol modulator from Corcept Therapeutics Inc., produced new and strong phase III results in treating platinum-resistant ovarian cancer. The company also has relacorilant in studies ...
Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia
Data demonstrated multiple clinical benefits beyond linear growth— NDA supported by data from three randomized, double-blind, ...
The Manila Times8h
Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights
As of December 31, 2024, Fortress' consolidated cash and cash equivalents totaled $57.3 million, compared to $58.9 million as ...
Vanda Pharmaceuticals submits NDA to FDA for Bysanti
Vanda Pharmaceuticals (VNDA) announced that a New Drug Application was submitted to the U.S. FDA requesting marketing approval of Bysanti for ...
Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure
(Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, today announced in addition to developing TH104 for the proposed ...